Trifluoromethanesulfonic Acid

Trifluoromethanesulfonic Acid

SCHEMBL1785091

Cn1cc[n+](-c2ccccc2)c1.O=S(=O)([O-])C(F)(F)F

nearest known ligand 0.38

Full drug profile on Sugi Atlas →

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
GPR3 P46089 2/20 0.38
KCNH2 Q12809 11/20 0.34
ACHE P22303 6/20 0.34
PTPN1 P18031 1/20 0.32
BCHE P06276 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20531179 0.87 NPSR1 (0.36) ACHEBCHE
SCHEMBL666882 0.82 BCHE (0.37) ACHEBCHE
Hydrochloric Acid SCHEMBL384461 0.80 BCHE (0.36) ACHEBCHE
Bromide SCHEMBL20531183 0.80 BCHE (0.36) ACHEBCHE
Iodide SCHEMBL3820103 0.80 BCHE (0.36) ACHEBCHE
Phosphoric Acid SCHEMBL20531175 0.79 TSHR (0.33) ACHEBCHE
SCHEMBL3628120 0.79 BCHE (0.32) ACHEBCHE
Trifluoromethanesulfonic Acid SCHEMBL30570819 0.79 GPR3 (0.46) GPR3KCNH2ACHEPTPN1
SCHEMBL29623928 0.79 BCHE (0.33) ACHEBCHE
SCHEMBL384826 0.79 ACHE (0.33) ACHEBCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9012899-B2 Electroluminescent metal complexes with nucleophilic carbene ligands BASF SE (DE) 2015-04-21 US disclosed
US-20130292660-A1 ELECTROLUMINESCENT METAL COMPLEXES WITH NUCLEOPHILIC CARBENE LIGANDS BASF SE (DE) 2013-11-07 US disclosed
US-8492749-B2 Electroluminescent metal complexes with nucleophilic carbene ligands BASF SE (DE) 2013-07-23 US disclosed
US-20110114922-A1 Electroluminescent Metal Complexes with Nucleophilic Carbene Ligands UDC IRELAND LIMITED (IE) 2011-05-19 US disclosed
EP-2080796-A1 Electroluminescent metal complexes with nucleophilic carbene ligands Ciba Holding Inc. (CH) 2009-07-22 EP disclosed
EP-1841834-B1 ELECTROLUMINESCENT METAL COMPLEXES WITH NUCLEOPHILIC CARBENE LIGANDS CIBA HOLDING INC (CH) 2009-05-06 EP disclosed
EP-1841834-A1 ELECTROLUMINESCENT METAL COMPLEXES WITH NUCLEOPHILIC CARBENE LIGANDS Ciba Specialty Chemicals Holding Inc. (CH) 2007-10-10 EP disclosed
WO-2006067074-A1 ELECTROLUMINESCENT METAL COMPLEXES WITH NUCLEOPHILIC CARBENE LIGANDS CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2006-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110114922-A1 Electroluminescent Metal Complexes with Nucleophilic Carbene Ligands OCIAD1, OCIAD2, C1S GPR3 2769/4885KCNH2 914/4885ACHE 2262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.